open access

Vol 84, No 8 (2013)
ARTICLES
Get Citation

Positron emission tomography (PET) in malignant ovarian tumors

Maciej Fularz, Paulina Adamiak, Rafał Czepczyński, Grażyna Jarząbek-Bielecka, Witold Kędzia, Marek Ruchała
DOI: 10.17772/gp/1630
·
Ginekol Pol 2013;84(8).

open access

Vol 84, No 8 (2013)
ARTICLES

Abstract

Accessibility of positron emission tomography integrated with computed tomography (PET/CT) has improved significantly in recent years. PET/CT with the use of 18F-deoxyglucose (FDG) is widely used in patients with ovarian malignancies at different stages of the management. FDG PET/CT shows high diagnostic accuracy in the differentiation of benign and malignant ovarian lesions with the exception of borderline tumors that may cause false negative results. Moreover, FDG PET/CT is used in some centers for preoperative staging and determining the prognosis of ovarian cancer. However, further studies including larger groups of patients are needed to confirm the applicability of FDG PET/CT in case of the two abovementioned indications. Until now, the best documented indication for FDG PET/CT in patients with ovarian cancer has been the detection of recurrence, especially in subjects with elevated CA125 marker and negative results of other imaging techniques. This review focuses on the applicability of PET with the use of FDG in ovarian malignancies and points out to the

Abstract

Accessibility of positron emission tomography integrated with computed tomography (PET/CT) has improved significantly in recent years. PET/CT with the use of 18F-deoxyglucose (FDG) is widely used in patients with ovarian malignancies at different stages of the management. FDG PET/CT shows high diagnostic accuracy in the differentiation of benign and malignant ovarian lesions with the exception of borderline tumors that may cause false negative results. Moreover, FDG PET/CT is used in some centers for preoperative staging and determining the prognosis of ovarian cancer. However, further studies including larger groups of patients are needed to confirm the applicability of FDG PET/CT in case of the two abovementioned indications. Until now, the best documented indication for FDG PET/CT in patients with ovarian cancer has been the detection of recurrence, especially in subjects with elevated CA125 marker and negative results of other imaging techniques. This review focuses on the applicability of PET with the use of FDG in ovarian malignancies and points out to the
Get Citation

Keywords

ovarian neoplasms, posittron-emission tomography, computed tomography

About this article
Title

Positron emission tomography (PET) in malignant ovarian tumors

Journal

Ginekologia Polska

Issue

Vol 84, No 8 (2013)

DOI

10.17772/gp/1630

Bibliographic record

Ginekol Pol 2013;84(8).

Keywords

ovarian neoplasms
posittron-emission tomography
computed tomography

Authors

Maciej Fularz
Paulina Adamiak
Rafał Czepczyński
Grażyna Jarząbek-Bielecka
Witold Kędzia
Marek Ruchała

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl